Translational Science Biocore

转化科学生物核心

• 批准号: 10626523
• 负责人: Kristina A. Matkowskyj
• 金额: $ 2.78万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-04-25 至 2028-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10626523
• 关键词: Accreditation; American; Animal Experiments; Animal Model; Animals; Appropriateness Review; Authorization documentation; Award; Basic Cancer Research; Body Fluids; Cancer Center; Cancer Center Support Grant; Catchment Area; Cell Line; Clinical; Clinical Data; Clinical Trials; Code; Collaborations; Collection; Comprehensive Cancer Center; Confidentiality of Patient Information; Consent; Consult; Data; Data Analyses; Databases; Development; Direct Costs; Disease; Ensure; Frozen Sections; Funding; Future; Genetic; Genomics; Grant; Health Surveys; Hematologic Neoplasms; Histopathology; Human; Human body; Image Analysis; Immunohistochemistry; Improve Access; In Situ Hybridization; Infrastructure; Institution; Institutional Review Boards; Instruction; Laboratories; Link; Malignant Neoplasms; Malignant neoplasm of brain; Mission; Modality; Modeling; Molecular; Molecular Analysis; Molecular Medicine; Molecular Profiling; Mus; NCI Center for Cancer Research; Paraffin Embedding; Pathologist; Pathology; Patients; Procedures; Process; Protocols documentation; Reproducibility; Research; Research Personnel; Research Project Grants; Research Support; Resources; Sampling; Science; Services; Site; Slide; Specific qualifier value; Specimen; Strategic Planning; System; Tissue Embedding; Tissue Microarray; Tissue Stains; Tissues; Translational Research; Tumor Tissue; United States National Institutes of Health; Universities; Update; Wisconsin; animal tissue; anticancer research; authority; biobank; clinically relevant; college; cost; digital pathology; experimental study; human model; human tissue; improved; innovation; instrumentation; machine learning algorithm; medical schools; member; molecular pathology; molecular phenotype; operation; precision medicine; programs; quantitative imaging; repository; translational cancer research; translational goal; tumor

PROJECT SUMMARY / ABSTRACT The mission of the Translational Science Biocore (TSB) is to facilitate cancer research by providing comprehensive services that enable cellular and molecular characterization of animal models and human- derived biospecimens. Aim 1 is to collect, annotate and distribute human-derived biospecimens. TSB operates with Institutional Review Board (IRB) approval to collect, store, annotate and distribute a wide variety of human tissues and body fluids that meet specified quality parameters. In the current Cancer Center Support Grant (CCSG) cycle, we expanded our protocol to enhance patient consenting and improve access to tissue and linked clinical data across multiple resources and repositories. TSB is authorized to serve as an ‘honest broker’ to provide investigators with clinical annotations that are coded to protect patient confidentiality. TSB also provides these services to UWCCC members with project-specific, IRB-approved protocols, such as investigator-initiated as well as national clinical trials. Aim 2 is to construct and distribute disease-specific tissue microarrays (TMAs). TSB pathologists review archival tissue blocks to identify specimens well suited for inclusion in each TMA which is then constructed by TSB staff. In the current CCSG cycle, 57 new TMAs with annotated clinical data were created, bringing the total to 115 which was facilitated by the purchase of an automated microarrayer funded by an NIH S10 award (S10OD023526). Aim 3 is to provide high quality services, expertise, and infrastructure in cellular, molecular, quantitative, and computational pathology. TSB pathologists and expert staff guide project development, conduct experiments, and interpret data that utilize human- and/or animal model-derived biospecimens. Our broad expertise and services span histopathology, morphometric analysis, quantitative analyses of specific molecular phenotypes, in situ hybridization, immunohistochemistry, and cell line authentication. TSB houses state-of-the-art instrumentation required for each of these services. During this CCSG cycle, TSB upgraded its digital pathology whole slide scanner and purchased systems to expand spatial and molecular profiling services. Impact on UWCCC: During the current CCSG cycle, TSB has supported the research of 129 unique UWCCC program members across all six scientific programs and distributed over 4,800 biospecimens. These members held 431 cancer-relevant research grants totaling $65.6M in annual direct costs, including 142 NCI grants, during this interval. By combining human and animal pathology cores from the previous CCSG cycle into central management with improved efficiency/coordination, we have increased the number of members served, types of biospecimens collected, number of samples processed/distributed, and the number of protocols/clinical trials supported. We have increased TMA creation and offer new spatial and molecular profiling services enabling members to perform innovative research that advances the UWCCC mission. Continued CCSG support allows us to provide members with priority access to biospecimens, extensive pathology services at low-cost and expert consultative support for their research needs.

项目总结/摘要 转化科学生物中心（TSB）的使命是通过提供 全面的服务，使细胞和分子表征的动物模型和人类， 衍生生物标本目的1是收集、注释和分发人源性生物标本。TSB运营 经机构审查委员会（IRB）批准，可以收集、储存、注释和分发各种人类 符合规定质量参数的组织和体液。在目前的癌症中心支持赠款中， （CCSG）周期，我们扩大了我们的协议，以加强患者的同意，并改善组织的获取， 跨多个资源和存储库的临床数据。TSB被授权作为一个“诚实的经纪人”， 为研究者提供编码的临床注释，以保护患者机密性。TSB还提供 这些服务的UWCCC成员与项目特定的，IRB批准的协议，如 以及国家临床试验。目的二是构建和分发疾病特异性组织芯片。 TSB病理学家审查存档组织块，以确定适合纳入每个TMA的标本， 然后由TSB工作人员建造。在当前的CCSG周期中，共纳入了57例新的具有注释临床数据的TMA。 创建，使总数达到115个，这是通过购买自动化微阵列仪提供的便利， NIH S10奖（S10 OD 023526）。目标3是提供高质量的服务、专业知识和基础设施， 细胞、分子、定量和计算病理学。TSB病理学家和专家工作人员指导项目 开发，进行实验，并解释利用人类和/或动物模型衍生的数据， 生物标本我们广泛的专业知识和服务涵盖组织病理学，形态学分析，定量分析， 特异性分子表型、原位杂交、免疫组织化学和细胞系分析 身份验证TSB拥有这些服务所需的最先进的仪器。在此 在CCSG周期内，TSB升级了其数字病理学全载玻片扫描仪，并购买了系统，以扩大空间 和分子分析服务对UWCCC的影响：在当前的CCSG周期内，TSB支持了 对所有六个科学计划中129个独特的UWCCC计划成员的研究，分布在4，800多个 生物标本这些成员持有431项与癌症相关的研究赠款，每年直接费用总计6560万美元， 包括142个NCI赠款。通过结合人类和动物病理学的核心， CCSG循环进入中央管理，提高效率/协调，我们增加了 服务的成员，收集的生物标本类型，处理/分发的样本数量，以及 支持的方案/临床试验。我们增加了TMA的创造，并提供新的空间和分子 分析服务，使成员能够进行创新的研究，推进UWCCC的使命。 持续的CCSG支持使我们能够为会员提供优先获取生物标本， 提供低成本的病理学服务，并为他们的研究需要提供专家咨询支持。